Immunoglobulin constant domains as targets for T-cell receptor-based treatment of multiple myeloma.
Despite major progress with chimeric antigen receptor (CAR) T-cell therapy, multiple myeloma (MM) remains largely incurable, and most patient relapse. To broaden therapeutic options and overcome antigen escape, we explored T-cell receptor (TCR)-based targeting of intracellular antigens derived from immunoglobulin (Ig)...